Pomerantz Law Firm Investigates Iovance Biotherapeutics Following Clinical Trial Data Discrepancy
Pomerantz LLP has launched an investigation into Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) regarding potential securities fraud or unlawful business practices. The probe follows a significant discrepancy in how the company communicated results from its Phase 2 IOV-LUN-202 clinical trial for lifileucel, an investigational therapy for non-squamous non-small cell lung cancer. While Iovance previously described the trial data as "Positive," subsequent reporting clarified that the results were merely "Consistent with Previously Reported Results." Specifically, one subgroup showed a response rate of 11.4%, which is lower than the 12.8% standard response rate for patients receiving typical treatments. This shift in narrative led to a sharp market reaction, with shares dropping over 35% on October 29, 2026.